Cost-effectiveness study comparing imatinib with interferon-α for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP)

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Chen, Zi ^b   Wang, Chun ^c   Xu, Xiaoping ^b   Feng, Weiwei ^a  

^a Novartis Pharmaceutical Corporation   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

China; CML; Cost effectiveness; Imatinib

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ARTICLE; CANCER SURVIVAL; CHINA; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MONEY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; SURVIVAL TIME;

EID: 72149097607     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00635.x     Document Type: Article

References (12)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA : American Cancer Society, 2007.
2. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006 81 : 973 988.
3. D'Antonio J. Chronic myelogenous leukemia. Clin J Oncol Nurs 2005 9 : 535 538.
4. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001 286 : 895 898.
5. Sawyers C. Chronic myeloid leukemia. NEJM 1999 340 : 1330 1340.
6. Holyoake TL. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001 113 : 11 23.
7. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 108 : 1809 1820.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. Available from: http://www.nccn.org/ professionals/physician-gls/PDF/cml.pdf [Accessed September 16, 2009 SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004 101 : 2574 2583.
9. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukemia. Pharmacoeconomics 2005 23 : 515 526.
10. Wang Q, Zhang C, Li D. Pharmacoeconomic evaluation of imatinib in the treatment of chronic myeloid leukemia [in Chinese]. Chin Pharma J 2005 40 : 472 474.
11. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. Pharmacoeconomics 2008 26 : 435 446.
12. Mataveli F, Calabro A, Mendes W, et al. Cost-effectiveness of imatinib versus interferon-α in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian public healthcare system perspective. Blood 2006 108 : 3314.